| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|---|---|---|---|---|---|---|
Revenue | |||||||
- | - | - | - | 0 | 0 | 0 | 0 |
Operating expenses | |||||||
Research and development | |||||||
8,128 | 6,817 | 2,022 | 3,191 | 32,638 | 14,577 | 12,201 | 7,370 |
General and administrative | |||||||
6,056 | 7,243 | 11,099 | 1,937 | 12,623 | 8,885 | 3,548 | 2,279 |
Goodwill impairment | |||||||
1,867 | 0 | - | - | - | - | - | - |
Total operating expenses | |||||||
16,051 | 14,060 | 13,121 | 5,128 | 45,261 | 23,462 | 15,749 | 9,649 |
Loss from operations | |||||||
-16,051 | -14,060 | -13,121 | -5,128 | -45,261 | -23,462 | -15,749 | -9,649 |
Interest income and other income, net | |||||||
- | - | - | - | 174 | 166 | - | - |
Interest and other income (expense), net | |||||||
- | - | - | - | - | - | 24 | - |
Other income (expense), net | |||||||
40 | -5 | 5 | -527 | - | - | - | - |
Net loss and comprehensive loss | |||||||
-16,011 | -14,065 | -13,116 | -5,655 | -45,087 | -23,296 | -15,725 | -9,649 |
Accretion of redeemable convertible preferred stock to redemption value | |||||||
- | - | - | - | - | - | 94 | 34 |
Net loss attributable to common stockholders | |||||||
- | - | - | - | - | - | -15,819 | -9,683 |
Net loss per share, basic and diluted | |||||||
-1.36 | -1.56 | -2.30 | -2.46 | -2.01 | -3.60 | -38.02 | -31.09 |
Weighted-average common shares outstanding, basic and diluted | |||||||
11,799 | 9,005 | 4,677 | 382 | 22,484 | 6,469 | 416 | 311 |
Net loss | |||||||
-16,011 | -14,065 | -13,116 | -5,655 | -45,087 | -23,296 | -15,725 | -9,649 |
Unrealized gains on marketable securities | |||||||
- | - | - | - | -55 | - | - | - |
Total other comprehensive income | |||||||
- | - | - | - | -55 | - | - | - |
Total comprehensive loss | |||||||
- | - | - | - | -45,142 | -23,296 | -15,725 | - |